Navigator Medicines, Inc., a clinical-stage biotech company leading the advancement of biologics for targeted immune regulation and restoration, today announced the appointments of Tausif (?Tosh') ...

retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...

GSK-3 activates transcription factors to induce PD-1 expression ... This might begin with additional mechanistic and translational studies that elucidate signaling pathways to understand the interplay ...

Figure 3 GP73 promotes EMT of cancer cells through different ... exosomal GP73 facilitates cell proliferation and metastasis through activating GSK-3β and MMP-related signaling pathways (107). However ...

Correspondence to Mark Nowell, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Box 29, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, ...

GSK expects 2025 sales growth between 3% and 5%, with core operating profit and EPS growth projected at 6% to 8%. Specialty medicines are anticipated to lead growth, with low double-digit ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks.

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover said to lift by between 3% and 5%. It said it expects further growth to be boosted by its strong ...

peak-year sales expected over £3 billion. Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. Brand New Membership Level: Benzinga Trade Alerts GSK plc ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

GSK started this year’s J.P. Morgan Healthcare Conference by acquiring precision biotech IDRx, including its phase 3-ready gastrointestinal ... of impact particular pathways or forms of ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the settlements, which will be funded through "existing resources," and said there ...